High-performance beating pattern function of human induced pluripotent stem cell-derived cardiomyocyte-based biosensors for hERG inhibition recognition.

[1]  A. Plowright,et al.  Heart regeneration: opportunities and challenges for drug discovery with novel chemical and therapeutic methods or agents. , 2014, Angewandte Chemie.

[2]  Kaiqi Su,et al.  A cardiomyocyte-based biosensor for antiarrhythmic drug evaluation by simultaneously monitoring cell growth and beating. , 2013, Biosensors & bioelectronics.

[3]  Donald M Bers,et al.  Screening Drug-Induced Arrhythmia Using Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes and Low-Impedance Microelectrode Arrays , 2013, Circulation.

[4]  N. Hu,et al.  Comparison between ECIS and LAPS for establishing a cardiomyocyte-based biosensor , 2013 .

[5]  Gareth J Waldron,et al.  Reducing safety-related drug attrition: the use of in vitro pharmacological profiling , 2012, Nature Reviews Drug Discovery.

[6]  M. Watzele,et al.  Dynamic monitoring of beating periodicity of stem cell‐derived cardiomyocytes as a predictive tool for preclinical safety assessment , 2012, British journal of pharmacology.

[7]  David S. Rosenbaum,et al.  Circadian rhythms govern cardiac repolarization and arrhythmogenesis , 2012, Nature.

[8]  M. Jonsson,et al.  Impedance-based detection of beating rhythm and proarrhythmic effects of compounds on stem cell-derived cardiomyocytes. , 2011, Assay and drug development technologies.

[9]  P. Schultz,et al.  Stepwise Chemically Induced Cardiomyocyte Specification of Human Embryonic Stem Cells , 2011 .

[10]  K. Kolaja,et al.  Use of human stem cell derived cardiomyocytes to examine sunitinib mediated cardiotoxicity and electrophysiological alterations. , 2011, Toxicology and applied pharmacology.

[11]  Lior Gepstein,et al.  Modelling the long QT syndrome with induced pluripotent stem cells , 2011, Nature.

[12]  Anthony E. Boitano,et al.  Chemical control of stem cell fate and developmental potential. , 2011, Angewandte Chemie.

[13]  Jules C Hancox,et al.  The hERG potassium channel and hERG screening for drug-induced torsades de pointes. , 2008, Pharmacology & therapeutics.

[14]  K. Sakurada,et al.  Regenerative medicine and stem cell based drug discovery. , 2008, Angewandte Chemie.

[15]  Qingjun Liu,et al.  Embryonic stem cells as a novel cell source of cell-based biosensors. , 2007, Biosensors & bioelectronics.

[16]  Stanley Nattel,et al.  Innovative approaches to anti-arrhythmic drug therapy , 2006, Nature Reviews Drug Discovery.

[17]  M. Sanguinetti,et al.  hERG potassium channels and cardiac arrhythmia , 2006, Nature.

[18]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[19]  A. Camm,et al.  Drug induced QT prolongation and torsades de pointes , 2003, Heart.

[20]  B. Fermini,et al.  The impact of drug-induced QT interval prolongation on drug discovery and development , 2003, Nature Reviews Drug Discovery.

[21]  Paul B Bennett,et al.  High throughput ion-channel pharmacology: planar-array-based voltage clamp. , 2003, Assay and drug development technologies.

[22]  D. Bers.  Cardiac excitation–contraction coupling , 2002, Nature.

[23]  H. Wellens,et al.  Progress in the understanding of cardiac early afterdepolarizations and torsades de pointes: time to revise current concepts. , 2000, Cardiovascular research.

[24]  J. Thomson,et al.  Embryonic stem cell lines derived from human blastocysts. , 1998, Science.

[25]  H. Oinuma,et al.  4'-[(4-Piperidyl)carbonyl]methanesulfonanilides as potent, selective, bioavailable class III antiarrhythmic agents. , 1990, Journal of medicinal chemistry.